Supporters say the drug, called Moxduo, would cut back on respiratory problems and allow for lower doses of both drugs.
However, not everyone is on board. "This is pure morphine and pure oxycodone,” Andrew Kolodny said.
Kolodny is an addiction specialist and heads Physicians for Responsible Opioid Prescribing, a group asking for more strict control of prescription painkillers. “This is a product that is very easy to misuse. Very easy to crush and snort or crush and inject,” he continued.
“We think it will exacerbate the opioid addiction epidemic," he told NPR.
The drug’s manufacturer is QRxPharma, they say too much of either drug can affect patients breathing or other problems like vomiting, nausea, and vertigo.
Harvard Medical School’s Dr. Joseph Audette adds the medicine could benefit many.
"And then suddenly we get in a terrible accident or have surgery and we need something. And the typical agents are used and suddenly all these terrible side effects come up."
Examiner.com reports the company expects the "addressable market" for the combo drug would lead to over 200 million prescriptions written yearly.
The FDA is meeting to debate the approval of Moxduo today.